tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

IFRX Stock Latest News

InflaRx’s Promising Drug Pipeline and Market Potential Drive Buy Rating
RatingsInflaRx’s Promising Drug Pipeline and Market Potential Drive Buy Rating
2d ago
IFRX
InflaRx price target raised to $10 from $7 at Guggenheim
PremiumThe Fly
InflaRx price target raised to $10 from $7 at Guggenheim
7d ago
IFRX
Promising Prospects for InflaRx’s Gohibic: Buy Rating Supported by Positive Phase 3 Developments and Market Potential
PremiumRatings
Promising Prospects for InflaRx’s Gohibic: Buy Rating Supported by Positive Phase 3 Developments and Market Potential
12d ago
IFRX
InflaRx N.V. Reports 2024 Results and Key Achievements
PremiumCompany Announcements
InflaRx N.V. Reports 2024 Results and Key Achievements
12d ago
IFRX
InflaRx Reports 2024 Results and Outlines 2025 Milestones
PremiumCompany Announcements
InflaRx Reports 2024 Results and Outlines 2025 Milestones
13d ago
6K
IFRX
InflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last year
PremiumThe FlyInflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last year
13d ago
IFRX
InflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last year
Premium
The Fly
InflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last year
13d ago
IFRX
Inflarx N.V. (IFRX) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Inflarx N.V. (IFRX) Q4 Earnings Cheat Sheet
15d ago
IFRX
InflaRx’s Gohibic Gains Momentum with Promising Clinical Data and Regulatory Support, Backing Buy Rating
PremiumRatings
InflaRx’s Gohibic Gains Momentum with Promising Clinical Data and Regulatory Support, Backing Buy Rating
26d ago
IFRX
InflaRx announces presentation of multiple posters on utility of vilobelimab
PremiumThe Fly
InflaRx announces presentation of multiple posters on utility of vilobelimab
26d ago
IFRX
InflaRx Concludes $30 Million Public Offering
PremiumCompany Announcements
InflaRx Concludes $30 Million Public Offering
1M ago
6K
IFRX
InflaRx 8.25M share Spot Secondary priced at $2.00
PremiumThe Fly
InflaRx 8.25M share Spot Secondary priced at $2.00
2M ago
IFRX
InflaRx announces ordinary shares and warrants offering, no amount given
PremiumThe FlyInflaRx announces ordinary shares and warrants offering, no amount given
2M ago
IFRX
InflaRx Secures EU Approval for GOHIBIC in Treating COVID-19-Induced ARDS
Premium
Company Announcements
InflaRx Secures EU Approval for GOHIBIC in Treating COVID-19-Induced ARDS
3M ago
6K
IFRX
InflaRx announces EC grants marketing authorization to Gohibic for ARDS
Premium
The Fly
InflaRx announces EC grants marketing authorization to Gohibic for ARDS
3M ago
IFRX
InflaRx Begins Phase 2a Trial for Innovative Anti-Inflammatory Drug
PremiumCompany Announcements
InflaRx Begins Phase 2a Trial for Innovative Anti-Inflammatory Drug
3M ago
6K
IFRX
InflaRx announces first patient dosed in 2a study of CSU, HS
PremiumThe Fly
InflaRx announces first patient dosed in 2a study of CSU, HS
3M ago
IFRX
InflaRx initiated with a Buy at Lucid Capital
PremiumThe Fly
InflaRx initiated with a Buy at Lucid Capital
4M ago
IFRX
InflaRx Gets EMA Nod for COVID-19 Treatment
PremiumCompany Announcements
InflaRx Gets EMA Nod for COVID-19 Treatment
5M ago
6K
IFRX
InflaRx receives positive CHMP opinion for GOHIBIC for SARS-CoV-2-induced ARDS
PremiumThe FlyInflaRx receives positive CHMP opinion for GOHIBIC for SARS-CoV-2-induced ARDS
5M ago
IFRX
InflaRx Reports Q3 2024 Financial Results and Progress
Premium
Company Announcements
InflaRx Reports Q3 2024 Financial Results and Progress
5M ago
IFRX
InflaRx Reports Rising Revenue Amidst Significant Losses
Premium
Company Announcements
InflaRx Reports Rising Revenue Amidst Significant Losses
5M ago
6K
IFRX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >